biostudies-literatureUnknown50(4)Kappel-Latif SMedical University of Vienna<h4>Background</h4>In operable esophageal cancer patients, neoadjuvant therapy benefits only those who respond to the treatment. The • Pancho trial represents the first prospective randomized trial evaluating the relevance of the mark53 status for predicting the effect of two different neoadjuvant chemotherapies.<h4>Method</h4>Biomarker analysis was conducted using the mark53 analysis. Calculation of patient number needed was based on a 60% rate of marker positivity, deduced from the results of a phase II pilot study.<h4>Results</h4>From 2007-2012, the • Pancho trial recruited 235 patients with operable esophageal cancer in Austria. A total of 181 patients were eligible and could be subjected to mark53 analysis and randomization. After randomizing 74 patients, the overall <i>TP53</i> mutatEuropean surgery : ACA : Acta chirurgica Austriaca160-166https://www.ebi.ac.uk/biostudies/studies/S-EPMC6290852biostudies-literature• Pancho trial (p53-adapted neoadjuvant chemotherapy for resectable esophageal cancer) completed-mutation rate of the marker higher than expected.PMC6290852Pancho trialists and for the Medical University of Vienna p53research groupBrugger SStiglbauer WDablander ENeumann HJSilye RDenk HOdelga VKain RPantucek FKlimpfinger MLichtenegger KEisterer WKuzmits RSporn SKappel-Latif SPrager GHofler GMerz PWeiß HKnauer MTeleky BUffmann MBernhart MKerjaschki DAberer BTrabe WFeichtinger JChott ASchermann MBeer FBonner ETomaselli FBerger FBeck ESagaster VOfner DBrammen LKarner JSchoppmann SFLeitner GEberl TBergmann NNaude SKandioler DFugger RTamandl DMoinfar FSedivy RKlepetko WThur MGuggenberger WEberhard NKessler TVeit DSmetana USega WHold MMostegel MHeinke BWeeber KRiegler MVeit THaid APourebrahim HAmmann KRiegler VViragos-Toth ITinchon CHohlagschwandtner MKadlecek VZwrtek RRogatsch HTschmelitsch JRapp NBrunner AGalowitsch SMittlbock MBraun OWesterhoff MHaller JGlaser KDanko GLang AOffner FNeuhold NDietze OGogl HPluschnig UEssenther MNader AAigner CSandurkov CGotzinger PSchoppmann SFrcena EHejna MBa-Ssalamah AMuhlbacher FRabl HKuhrer IGnant MFriedl JHudec MMikuz GGrunberger TWustinger CKristandl EKeil FMaderdonner MHobling WMuhlmann GLangle FKees-Belyus MNiederle BWenzl EMuhlmann JBraun OMWrba FHeinz GPober MWolf BLercher-Lueger MBichler CKainz HAdolf WFortelny RKitzwogerer MStrasser-Weipl KSchenk TMetz SOsterreicher CRoka SRoka RKosak DKastner UJakesz RWerba GHartmann BZitt MThalhammer SMaier HFreibauer CZacherl Jfalse• Pancho trial (p53-adapted neoadjuvant chemotherapy for resectable esophageal cancer) completed-mutation rate of the marker higher than expected.<h4>Background</h4>In operable esophageal cancer patients, neoadjuvant therapy benefits only those who respond to the treatment. The • Pancho trial represents the first prospective randomized trial evaluating the relevance of the mark53 status for predicting the effect of two different neoadjuvant chemotherapies.<h4>Method</h4>Biomarker analysis was conducted using the mark53 analysis. Calculation of patient number needed was based on a 60% rate of marker positivity, deduced from the results of a phase II pilot study.<h4>Results</h4>From 2007-2012, the • Pancho trial recruited 235 patients with operable esophageal cancer in Austria. A total of 181 patients were eligible and could be subjected to mark53 analysis and randomization. After randomizing 74 patients, the overall <i>TP53</i> mutat2018-01-01T00:00:00Z20182025-04-04T22:53:17.677Z2019-03-27T00:12:25ZS-EPMC62908523055983110.1007/s10353-018-0527-z